Latest Breaking News On - Drug administration approves opdivo - Page 1 : comparemela.com

In CheckMate -577, Opdivo 1 Approval expands the role of Opdivo in earlier stages of disease, with two indications in the adjuvant setting across three types of cancer 1 PRINCETON, NJ, USA I May 20, 2021 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). 1 The approval is based on results from the Phase 3 CheckMate -577 trial that evaluated Opdivo (n=532) compared to placebo (n=262) in esophageal or GEJ cancer patients with residual pathologic disease following neoadjuvant CRT and complete resection.

Baylor universityUnited statesSouth koreaRonanj kellyAdam lenkowskyI bristol myers squibbNeoadjuvant downstagingNeoadjuvant chemoradiotherapyGastroenterol hepatolBristol myers squibbWw caruth jrAssociation with baseline variablesBristol myers squibb companyTime oncology review pilot programVirtual congressDrug administration approves opdivo